Keywords
How to Cite
Abstract
An active introduction of screening programs potentially leads to a significant increase in the proportion of patients with early forms of non-small cell lung cancer. Surgical treatment, which is the standard of care for localized forms, due to functional limitations can be performed only in 65-70% of patients. The solution to this problem can be found in the improvement of the results of radiotherapy by using modern equipment, the planning systems, improved fractionation schemes and introduction of methods for summing radiation doses. Stereotactic radiotherapy allows high-precision delivery of high radiation dose to tumor with a minimal damage to surrounding healthy tissues. In this literature review based on the analysis of a large number of publications we show that it is not yet possible to make valid conclusions about the effectiveness and safety of stereotactic radiation therapy as an alternative to the surgical methods. It is necessary to plan and conduct randomized trials without further delay taking into account the expected high relevance of the method.References
Борисова Т.Н., Назаренко А.В., Ткачев С.И. и др. Стереотаксическая гипофракционная радиотерапия больных раком лёгкого I-IIA клинической стадии: роль оценки SUVMAX при ПЭТ/КТ с 18F-ФДГ для контроля за результатами лечения // Вопросы онкологии. - 2017. - Т. 63(4). - С. 632-638.
Bertolaccini L., Terzi A., Ricchetti F., Alongi F. Surgery or stereotactic ablative radiation therapy: how will be treated operable patients with early stage not small cell lung cancer in the next future? // Ann. Transl. Med. - 2015. - Vol. 3(2). - P. 25.
Bilal H., Mahmood S., Rajashankerc B., Shaha R. Is radiofrequency ablation more effective than stereotactic ablative radiotherapy in patients with early stage medically inoperable non-small cell lung cancer? // Interactive Cardiovascular and Thoracic Surgeryio - 2012. - Vol. 15. - P. 258-265.
Bollineni V.R., Widder J., Pruim J., Langendijk J.A., Wiegman E.M. Residual 18F-FDG-PET Uptake 12 Weeks After Stereotactic Ablative Radiotherapy for Stage I Non-Small-Cell Lung Cancer Predicts Local Control // Radiation Oncol. Biol. Phys. - 2012. - Vol. 83. - № 4. - P 551555.
Cao С., Gupta S., Chandrakumar D. et al. Meta-analysis of intentional sublobar resections versus lobectomy for early stage non-small cell lung cancer // Ann. Cardiothorac. Surg. - 2014. - Vol. 3(2). - P 134-141.
Chan O.S.H., Lee V.H.F., Mok T.S.K. et al. The role of radiotherapy in epidermal growth factor receptor mutation-positive patients with oligoprogression: a matchedcohort analysis // Clin. Oncol. - 2017. - Vol. 29. - P 568-575.
Chang J.Y, Senan S., Paul M.A. et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I nonsmall-cell lung cancer: a pooled analysis of two randomised trials // Lancet Oncol. - 2015. - Vol. 16. - № 6. - P. 630-637.
Dziedzic R., Zurek W., Marjanski T. et al. Stage I nonsmall-cell lung cancer: long-term results of lobectomy versus sublobar resection from the Polish National Lung Cancer Registry // Eur. J. Cardiothorac. Surg. - 2017. - Vol. 52(2). - P. 363-369.
Gan G., Weickhardt A.J., Scheier B. et al. Stereotactic Radiotherapy Can Safely and Durably Control Sites of Extra-CNS Oligoprogressive Disease in ALK-Positive Lung Cancer Patients on Crizotinib // Int. J. Radiat. Oncol. Biol. Phys. - 2014. - Vol. 88(4). - P 892-898.
Grills I.S., Mangona V.S., Welsh R. et al. Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer // J. Clin. Oncol. - 2010. - Vol. 28. -№ 6. - P 928-935.
Grills I.S., Hope A.J., Guckenberger M. et al. A Collaborative Analysis of Stereotactic Lung Radiotherapy Outcomes for Early-Stage Non-Small-Cell Lung Cancer Using Daily Online Cone-Beam Computed Tomography Image-Guided Radiotherapy // J. Thorac. Oncol. - 2012. - Vol. 7. - P. 1382-1393.
Haasbeek C.J., Lagerwaard F.J., Slotman B.J., Senan S. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer // J. Thorac. Oncol. - 2011. - Vol. 6. - P. 2036-2043.
Kestin L., Grills I., Guckenberger M. et al. Dose-response relationship with clinical outcome for lung stereotactic body radiotherapy (СТЛТ) delivered via online image guidance // Radiotherapy and oncology: journal of the European Society for Therapeutic Radiology and Oncology. - 2014. - Vol. 110. - P. 499- 504.
Lee S., Song S.Y, Kim S.S. et al. Feasible Optimization of Stereotactic Ablative Radiotherapy Dose by Tumor Size for Stage I Non- Small Cell Lung Cancer // Clinical Lung Cancer. - 2017. - DOI: 10.1016/j.cllc.2017.11.001
Ma L. and Xiang J. Clinical outcomes of video-assisted thoracic surgery and stereotactic body radiation therapy for early-stage non-small cell lung cancer: A meta-analysis // Thorac. Cancer. - 2016. - Vol. 7(4). - P. 442-451.
Mahmood S., Bilal H., Faivre-Finn C., Shahb R. Is stereotactic ablative radiotherapy equivalent to sublobar resection in high-risk surgical patients with Stage I nonsmall-cell lung cancer? // Interact. Cardiovasc. Thorac. Surg. - 2013. - Vol. 17(5). - P 845-853.
McDonald F., Hanna G.G. Oligoprogressive Oncogene-addicted Lung Tumours: Does Stereotactic Body Radiotherapy Have a Role? Introducing the HALT Trial // Clinical Oncology. - 2017. - DOI: 10.1016/j.clon.2017.10.013
Onishi H., Shirato H., Nagata Y Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study // J. Thorac. Oncol. - 2007. - Vol. 2. - P 94-100.
Palma D., Visser O., Lagerwaard F.J. et al. Impact of Introducing Stereotactic Lung Radiotherapy for Elderly Patients With Stage I Non-Small-Cell Lung Cancer: A Population-Based Time-Trend Analysis // J Clin Oncol. - 2010. -
Ricardi U., Badellino S., Filippi A.R. Stereotactic radiotherapy for early stage non-small cell lung cancer // Radiat. Oncol. J. - 2015. - Vol. 33(2). - P. 57-65.
Roesch J., Panje C. Sterzing F., Mantel F., Nestle U. Andratschke N., Guckenberger M. СТЛТ for centrally localized NSCLC - What is too central? // Radiat. Oncol. - 2016. - Vol. 11. - P. 157-165.
Senthi S., Lagerwaard F.G., Haasbeek C.J.A., Slotman B.J., Senan S. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis // Lancet Oncol. - 2012. - Vol. 13. - P. 802-809.
Snee M.P, McParland L., Collinson F. et al. The SABRTooth feasibility trial protocol: a study to determine the feasibility and acceptability of conducting a phase III randomised controlled trial comparing stereotactic ablative radiotherapy (SABR) with surgery in patients with peripheral stage I non-small cell lung cancer (NSCLC) considered to be at higher risk of complications from surgical resection // Pilot and Feasibility Studies. - 2016. - Vol. 2. - P. 5. - 10.1186/s40814-016-0046 2 DOI: 10.1186/s40814-016-00462
Singh A.K., Suescun J.A.G., Stephans K.L. A Phase 2 Randomized Study of 2 Stereotactic Body Radiation Therapy Regimens for Medically Inoperable Patients With Node-Negative, Peripheral Non- Small Cell Lung Cancer // Int. J. Radiat. Oncol. Biol. Phys. - 2017. - 98. - P 221-222.
Shirvani S.M., Jiang J., Chang J.Y et al. Lobectomy, Sublobar Resection, and Stereotactic Radiation for Early-Stage Non-Small Cell Lung Cancers in the Elderly // JAMA Surg. - 2014. - Vol. 149(12). - P. 1244-1253.
Stahl J.M., Ross R., Harder E.M. et al. The Effect of Biologically Effective Dose and Radiation Treatment Schedule on Overall Survival in Stage I Non-Small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy // Int. J. Radiat. Oncol. Biol. Phys. - 2016. - Vol. 96. - P 1011-1020.
Sun B., Brooks E.D., Komaki R.U. et al. 7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung Cancer: Results of a phase 2 clinical trial // Cancer. - 2017. - Vol. 123(16). - Р. 3031-3039.
Timmerman R., Paulus R., Galvin J. et al. Stereotactic body radiation therapy for inoperable early stage lung cancer // JAMA. - 2010. - Vol. 303. - № 11. - P. 1070-1076.
Uzel E.K., Abacioglu U. Treatment of Early Stage Non-Small Cell Lung Cancer: Surgery or Stereotactic Ablative Radiotherapy? // Balkan Med. J.- 2015. - Vol. 32(1). -P. 8-16.
Yerokun B.A., Yang C.J., Gulack B.C. et al. A national analysis of wedge resection versus stereotactic body radiation therapy for stage IA non-small cell lung cancer // J. Thorac. Cardiovasc. Surg. - 2017. - Vol. 154(2). -P. 675-686.
Weickhardt A.J., Scheier B., Burke J.M. et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene addicted non-small cell lung cancer // J. Thorac. Oncol. -2012. - Vol. 7(12). - Р 1807-1814.
White A., Swanson S.J. Surgery versus stereotactic ablative radiotherapy (SABR) for early-stage non-small cell lung cancer: less is not more // J. Thorac. Dis. - 2016. - Vol. 8(4). - P. 399-405.
Zhang J., Yang F., Li B. et al. Which is the optimal biologically effective dose of stereotactic body radiotherapy for Stage I non-small-cell lung cancer? A meta-analysis // Int. J. Radiat. Oncol. Biol. Phys. - 2011. - Vol. 81. -№ 4. - P. 305-316.
Zhang J., Kong L., Jiao Q., Li M., Yu J. Stereotactic ablative radiotherapy in treatment of early-stage non-small cell lung cancer: Unsolved questions and frontiers ahead // Cancer Lett. - 2017. - Vol. 401. - P. 46-52.
Zheng X., Schipper M., Kidwell K. et al. Survival outcome after stereotactic body radiation therapy and surgery for stage I non-small cell lung cancer: a meta-analysis // Int. J. Radiat. Oncol. Biol. Phys. - 2014. - Vol. 90. - № 3. - P 603-611.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2018